A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
A Phase IB/II Study of Blinatumomab in Patients With Pre B-cell Acute Lymphoblastic Leukemia (ALL) and B-cell Non-Hodgkin Lymphoma (NHL) as Post-allogeneic Stem Cell Transplant (Allo-HSCT) Remission Maintenance
Sponsor: Amgen
A PHASE1/PHASE2 clinical study on Acute Lymphoblastic Leukemia and B-cell Non Hodgkin Lymphoma, this trial is ongoing. The trial is conducted by Amgen and has accumulated 14 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Jun 2025 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2023 — Jun 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 9 earlier versions
-
Jun 2022 — Jun 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Jul 2019 — Jul 2020 [monthly]
Recruiting PHASE1
Phase: EARLY_PHASE1 → PHASE1
-
Nov 2018 — Jul 2019 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Recruiting EARLY_PHASE1
-
Nov 2017 — Jun 2018 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Nov 2017 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
For direct contact, visit the study record on ClinicalTrials.gov .